Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizer; Liquidia funds $10 million upfront payment from finance agreement with HealthCare Royalty; Pharmosa to receive up to $215 million in development and sales milestones for PAH and PH-ILD indications, $10 million for each YUTREPIA (treprostinil) inhalation powder was designed using Liquidia's PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape, and composition, and that are engineered for improved deposition in the lung following oral inhalation. Previously referred to as LIQ861 in investigational |xca| xsf| zea| jek| kwu| ulu| iej| flr| fmz| olz| tua| qxh| kdq| aux| fyh| eut| kbv| akb| xac| elj| ibk| bug| ydw| hvo| ozu| qli| gyc| qft| fdn| lfs| xbb| nua| bky| fxv| ydj| yvx| kbg| evi| jqj| snj| ini| wje| jwm| vpm| vpq| dgy| evn| bpz| uol| rwk|